Literature DB >> 27885435

Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients.

B Szekely1, Zs I Nagy2, Zs Farago2, O Kiss2, G Lotz2, K A Kovacs2, L Madaras2, N Udvarhelyi3, M Dank4, Gy Szentmartoni4, Zs Baranyai5, L Harsanyi5, A M Tőkés2,6, Jozsef Timar2, A M Szasz2, J Kulka2.   

Abstract

Phenotypical change in metastatic breast carcinoma has widely been accepted as an inherent biological feature rather than technical fault. We analyzed the immunohistochemical phenotype and histopathological features of 25 primary breast carcinomas and 90 corresponding distant metastases in 23 organs retrospectively. Histological slides were reviewed for prognostic and predictive factors. Overall, metastases were more similar to each other and often differed from the primary tumor. We created a 3-step grouping system based on the localization of metastases. Regions: tumors metastasizing to the abdominal region were likely to lose ER (p = 0.002); we detected loss of PR in metastases to the thorax (p = 0.039) and abdomen (p < 0.001). Organ systems: loss of ER and PR was observed in metastases to the gastrointestinal system (p = 0.026 and p = 0.001, respectively), in the respiratory system only the loss of PR was significant (p = 0.05). Individual organs: the primaries were likely to lose the hormone receptors in liver metastases (ER p = 0.026; PR p = 0.004). In lung metastases only loss of PR was apparent (p = 0.049). We did not observe significant change in HER2 status, regarding Ki67 change occurred only in bone metastases compared to the primary (p = 0.048). 7/25 patients' distant metastases had heterogeneous immunoprofiles. The later the metastasis was discovered the more likely it had a differing IHC profile compared to the primary tumor, patients who had longer OS had a higher chance to develop a discordant metastasis. Immunoprofile of metastases may differ from primary breast cancer and from each other, probably resulting in different response to therapy.

Entities:  

Keywords:  Autopsy; Breast cancer; Immunophenotype; Metastasis; Subtype; Survival

Mesh:

Year:  2016        PMID: 27885435     DOI: 10.1007/s10585-016-9830-x

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  34 in total

1.  Genetic and phenotypic diversity in breast tumor metastases.

Authors:  Vanessa Almendro; Hee Jung Kim; Yu-Kang Cheng; Mithat Gönen; Shalev Itzkovitz; Pedram Argani; Alexander van Oudenaarden; Saraswati Sukumar; Franziska Michor; Kornelia Polyak
Journal:  Cancer Res       Date:  2014-01-21       Impact factor: 12.701

Review 2.  Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.

Authors:  Sabrina Rossi; Michele Basso; Antonia Strippoli; Vincenzo Dadduzio; Eleonora Cerchiaro; Rosalba Barile; Ettore D'Argento; Alessandra Cassano; Giovanni Schinzari; Carlo Barone
Journal:  Clin Breast Cancer       Date:  2015-03-25       Impact factor: 3.225

3.  Central nervous system metastasis from breast carcinoma. Autopsy study.

Authors:  Y Tsukada; A Fouad; J W Pickren; W W Lane
Journal:  Cancer       Date:  1983-12-15       Impact factor: 6.860

4.  Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

Authors:  C Liedtke; K Broglio; S Moulder; L Hsu; S-W Kau; W F Symmans; C Albarracin; F Meric-Bernstam; W Woodward; R L Theriault; L Kiesel; G N Hortobagyi; L Pusztai; A M Gonzalez-Angulo
Journal:  Ann Oncol       Date:  2009-07-12       Impact factor: 32.976

5.  Variation in receptor status between primary and metastatic breast cancer.

Authors:  I M Holdaway; J V Bowditch
Journal:  Cancer       Date:  1983-08-01       Impact factor: 6.860

6.  Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer.

Authors:  Carmen Gomez-Fernandez; Yahya Daneshbod; Mehdi Nassiri; Clara Milikowski; Consuelo Alvarez; Mehrdad Nadji
Journal:  Am J Clin Pathol       Date:  2008-12       Impact factor: 2.493

7.  Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.

Authors:  Reiki Nishimura; Tomofumi Osako; Yasuhiro Okumura; Rumiko Tashima; Yasuo Toyozumi; Nobuyuki Arima
Journal:  World J Surg Oncol       Date:  2011-10-17       Impact factor: 2.754

8.  Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies.

Authors:  M Nielsen; J L Thomsen; S Primdahl; U Dyreborg; J A Andersen
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

9.  The landscape of metastatic progression patterns across major human cancers.

Authors:  Jan Budczies; Moritz von Winterfeld; Frederick Klauschen; Michael Bockmayr; Jochen K Lennerz; Carsten Denkert; Thomas Wolf; Arne Warth; Manfred Dietel; Ioannis Anagnostopoulos; Wilko Weichert; Daniel Wittschieber; Albrecht Stenzinger
Journal:  Oncotarget       Date:  2015-01-01

10.  Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

Authors:  Muhammed Murtaza; Sarah-Jane Dawson; Katherine Pogrebniak; Oscar M Rueda; Elena Provenzano; John Grant; Suet-Feung Chin; Dana W Y Tsui; Francesco Marass; Davina Gale; H Raza Ali; Pankti Shah; Tania Contente-Cuomo; Hossein Farahani; Karey Shumansky; Zoya Kingsbury; Sean Humphray; David Bentley; Sohrab P Shah; Matthew Wallis; Nitzan Rosenfeld; Carlos Caldas
Journal:  Nat Commun       Date:  2015-11-04       Impact factor: 14.919

View more
  2 in total

1.  Timeline metastatic progression: in the wake of the « seed and soil » theory.

Authors:  Aymeric Amelot; Louis-Marie Terrier; Jean-Jacques Mazeron; Charles-Ambroise Valery; Philippe Cornu; Alexandre Carpentier; Marc Leveque
Journal:  Med Oncol       Date:  2017-10-06       Impact factor: 3.064

2.  Molecular Protein and Expression Profile in the Primary Tumors of Clear Cell Renal Carcinoma and Metastases.

Authors:  Liudmila V Spirina; Zahar A Yurmazov; Alexey K Gorbunov; Evgeny A Usynin; Nadezhda A Lushnikova; Irina V Kovaleva
Journal:  Cells       Date:  2020-07-13       Impact factor: 7.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.